Indian medicine has traditionally used Phyllanthus amarus to treat a variety of conditions, including hepatitis B. This study examines the potential anti-HIV-1 capabilities of the subject. The aim was to assess the effectiveness of P. amarus extracts and quercetin, a bioactive molecule, in suppressing HIV-1 expression. We utilised in vitro and in silico techniques to investigate the antiviral properties. We synthesised and analysed crude extracts from the plant to determine their capacity to suppress HIV-1 in MT-2 cells. We assessed the presence of the HIV-1 gag p24 protein using ELISA. Additionally, we evaluated the suppressive effects on HIV-1 reverse transcriptase (RT) using an HIV-RT assay kit. This study investigates Quercetin's binding interactions with HIV-1 p24 and RT proteins through molecular docking experiments. Our study's findings demonstrate that methanol extracts of P. amarus effectively suppressed HIV-1 p24 expression. Specifically, the leaf and seed extracts exhibited inhibition rates of 87.52 ± 1.96% and 88.74 ± 1.03%, respectively, at a concentration of 200 µg/ml. The HIV-RT assay showed that leaf extracts inhibited HIV by 85.55 ± 1.65%, whereas seed extracts inhibited it by 88.91 ± 1.22%. Molecular docking showed that quercetin has strong interactions with the NF-kappa B protein, which supports its antiviral activity. P. amarus and its bioactive part, quercetin, are very good at fighting HIV-1. They may do this by stopping the virus from replicating and stopping reverse transcriptase. The results highlight the therapeutic potential of P. amarus in developing innovative anti-HIV therapies. Additional research is necessary to investigate its clinical uses